Status:
COMPLETED
Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer
Lead Sponsor:
Konstantin Dragnev
Collaborating Sponsors:
Ligand Pharmaceuticals
Genentech, Inc.
Conditions:
Carcinoma, Non-small-cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is app...
Detailed Description
This is a single institution open label phase II trial. Consecutive, eligible patients presenting with the diagnosis of advanced NSCLC are to be enrolled in this study. All eligible patients will rece...
Eligibility Criteria
Inclusion
- Advanced NSCLC
- Prior chemotherapy or radiotherapy is allowed.
Exclusion
- Hepatic or renal dysfunction
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00125359
Start Date
August 1 2005
End Date
March 1 2014
Last Update
January 8 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756
2
Mount Sinai School of Medicine
New York, New York, United States, 10029